ESSEX BIO-TECH Reports Annual Profit of HK$318 Million, Up 3.54% Year-on-Year

Stock News03-23

ESSEX BIO-TECH (01061) announced its full-year results for the period ended December 31, 2025. The company achieved revenue of HK$1.814 billion, representing an increase of 8.62% compared to the previous year. Annual profit was HK$318 million, a rise of 3.54% year-on-year. Earnings per share were HK56.10 cents. The board proposed a final dividend of HK$0.07 per share.

In the fiscal year ended December 31, 2025, the Ophthalmology segment contributed approximately HK$835 million to the group's revenue, an increase of 8.2% compared to 2024. The Surgery segment recorded total revenue of about HK$896 million for the year, up 1.8% from 2024. Revenue from the Healthcare and Partner Services segment amounted to approximately HK$82.9 million, marking a significant increase of 350% compared to the previous year.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1170662886?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-23 19:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1170662886","market":"us","top_or_hot":-1,"title":"ESSEX BIO-TECH Reports Annual Profit of HK$318 Million, Up 3.54% Year-on-Year","media":"Stock News","content":"<p>ESSEX BIO-TECH (01061) announced its full-year results for the period ended December 31, 2025. The company achieved revenue of HK$1.814 billion, representing an increase of 8.62% compared to the previous year. Annual profit was HK$318 million, a rise of 3.54% year-on-year. Earnings per share were HK56.10 cents. The board proposed a final dividend of HK$0.07 per share.</p>\n<p>In the fiscal year ended December 31, 2025, the Ophthalmology segment contributed approximately HK$835 million to the group's revenue, an increase of 8.2% compared to 2024. The Surgery segment recorded total revenue of about HK$896 million for the year, up 1.8% from 2024. Revenue from the Healthcare and Partner Services segment amounted to approximately HK$82.9 million, marking a significant increase of 350% compared to the previous year.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ESSEX BIO-TECH Reports Annual Profit of HK$318 Million, Up 3.54% Year-on-Year</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nESSEX BIO-TECH Reports Annual Profit of HK$318 Million, Up 3.54% Year-on-Year\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-23 19:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>ESSEX BIO-TECH (01061) announced its full-year results for the period ended December 31, 2025. The company achieved revenue of HK$1.814 billion, representing an increase of 8.62% compared to the previous year. Annual profit was HK$318 million, a rise of 3.54% year-on-year. Earnings per share were HK56.10 cents. The board proposed a final dividend of HK$0.07 per share.</p>\n<p>In the fiscal year ended December 31, 2025, the Ophthalmology segment contributed approximately HK$835 million to the group's revenue, an increase of 8.2% compared to 2024. The Surgery segment recorded total revenue of about HK$896 million for the year, up 1.8% from 2024. Revenue from the Healthcare and Partner Services segment amounted to approximately HK$82.9 million, marking a significant increase of 350% compared to the previous year.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1170662886","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1170662886","pubTimestamp":1774264938,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"ESSEX BIO-TECH (01061) announced its full-year results for the period ended December 31, 2025. The company achieved revenue of HK$1.814 billion, representing an increase of 8.62% compared to the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","01061":"亿胜生物科技"},"translate_title":"亿胜生物公布全年盈利3.18亿港元同比增长3.54%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01061":1},"content_text":"ESSEX BIO-TECH (01061) announced its full-year results for the period ended December 31, 2025. The company achieved revenue of HK$1.814 billion, representing an increase of 8.62% compared to the previous year. Annual profit was HK$318 million, a rise of 3.54% year-on-year. Earnings per share were HK56.10 cents. The board proposed a final dividend of HK$0.07 per share.\nIn the fiscal year ended December 31, 2025, the Ophthalmology segment contributed approximately HK$835 million to the group's revenue, an increase of 8.2% compared to 2024. The Surgery segment recorded total revenue of about HK$896 million for the year, up 1.8% from 2024. Revenue from the Healthcare and Partner Services segment amounted to approximately HK$82.9 million, marking a significant increase of 350% compared to the previous year.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1170662886","isCrawlerRequest":true}